TABLE 3.
Summary of ritonavir pharmacokinetic parameters following administration of ritonavir in combination with saquinavir-SGC for 13 days in healthy HIV-negative volunteers
| Parameter | Value for groupa:
|
|||
|---|---|---|---|---|
| A | C | D | E | |
| AUC0–24h | ||||
| Mean (SD) | 11,721 (5043) | 10,344 (7,061) | 7,879 (2,087) | 23,869 (11,774) |
| Geometric mean | 10,711 | 8,755 | 7,647 | 21,216 |
| Median (range) | 11,540 (5,794–17,872) | 9,871 (3,449–27,371) | 7,613 (5,151–11,544) | 19,968 (8,808–40,507) |
| Cmax | ||||
| Mean (SD) | 1,001 (411) | 1,019 (922) | 676 (139) | 2,268 (1,170) |
| Geometric mean | 925 | 796 | 663 | 2,028 |
| Median (range) | 1,011 (519–1,670) | 835 (268–3,360) | 671 (512–855) | 2,110 (982–4,610) |
| Cmin | ||||
| Mean (SD) | 92 (65) | 61 (45) | 74 (51) | 253 (250) |
| Geometric mean | 76 | 48 | 52 | 171 |
| Median (range) | 67 (31–216) | 47 (15–145) | 63 (5–145) | 189 (42–817) |
a
Dosing for groups was as follows: for group A (n = 8), 1,200 mg of saquinavir-SGC three times a day; for group C (n = 10), 1,600 mg of saquinavir-SGC plus 100 mg of ritonavir (both once daily); for group D (n = 9), 1,800 mg of saquinavir-SGC plus 100 mg of ritonavir (both once daily); and for group E (n = 9), 1,200 mg of saquinavir-SGC plus 200 mg of ritonavir (both once daily).